What Janux Therapeutics, Inc.'s executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 0 | 12 |
| Total trades | 1 | 32 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 0 | 353,366 |
| Disposed | 123,840 | 172,301 |
| Net activity | −123,840 | +181,065 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Campbell David Alan | President and CEO | Jul 31 | Gift · G | −123,840 | — | — | 264,742 |
| Campbell David Alan | President and CEO | Jul 08 | Exercise / conversion · M | +7,000 | $4.21 | +$29.5K | 388,582 |
| Ra Capital MANAGEMENT, L.p. | Director | Jun 11 | Grant / award · A | +5,500 | — | — | 11,750 |
| Capps Vickie L | Director | Jun 11 | Grant / award · A | +5,500 | — | — | 79,598 |
| Barrett Ronald W | Director | Jun 11 | Grant / award · A | +5,500 | — | — | 11,750 |
| Kung Winston | Director | Jun 11 | Grant / award · A | +5,500 | — | — | 11,750 |
| Dobmeier Eric | Director | Jun 11 | Grant / award · A | +5,500 | — | — | 15,481 |
| Hernday Natasha | Director | Jun 11 | Grant / award · A | +5,500 | — | — | 15,481 |
| Simson Jake | Director | Jun 11 | Grant / award · A | +5,500 | — | — | 11,750 |
| Doyle Janeen Noel | Chief Corp. & Bus. Dev. Ofcr | Jun 02 | Open-market sale · S | −4,059 | $14.03 | −$56.9K | 75,941 |
| Dobek Maria | Vice President, Accounting | May 11 | Open-market sale · S | −2,038 | $14.17 | −$28.9K | 32,270 |
| Go William | Chief Medical Officer | Feb 02 | Grant / award · A | +44,000 | — | — | 44,000 |
| Winter Charles M. | Chief Technical Officer | Jan 02 | Grant / award · A | +28,600 | — | — | 106,321 |
| Winter Charles M. | Chief Technical Officer | Jan 02 | Open-market sale · S | −2,401 | $13.73 | −$33K | 77,721 |
| DiRaimondo Thomas | Chief Scientific Officer | Jan 02 | Grant / award · A | +31,400 | — | — | 155,825 |
| DiRaimondo Thomas | Chief Scientific Officer | Jan 02 | Open-market sale · S | −2,505 | $13.73 | −$34.4K | 124,425 |
| McIver Zachariah | Chief Medical Officer | Jan 02 | Grant / award · A | +29,000 | — | — | 52,286 |
| McIver Zachariah | Chief Medical Officer | Jan 02 | Open-market sale · S | −2,714 | $13.73 | −$37.3K | 23,286 |
| Campbell David Alan | President and CEO | Jan 02 | Grant / award · A | +96,600 | — | — | 381,582 |
| Campbell David Alan | President and CEO | Jan 02 | Open-market sale · S | −8,072 | $13.73 | −$111K | 284,982 |
Loading...
